Arterial Stents Market Projected to Reach USD 42.48 Billion by 2032 – Fact.MR

By the conclusion of the 2022–2032 projection period, the global arterial stents market is anticipated to be worth US $42 billion, according to Fact.MR, a company that provides market research and competitive information.

From 2022 to 2032, demand is expected to increase at a 10.5% value CAGR, with the potential to reach US$42,475.3 million by the end of the assessment period.

Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4713

The global arterial stents market, valued at USD 14.14 billion in 2021, is projected to grow to USD 15.65 billion in 2022. From 2022 to 2032, demand is expected to increase at a 10.5% CAGR, reaching USD 42.48 billion by 2032.

Key drivers include rising cardiovascular diseases, obesity, and a preference for minimally invasive procedures. Coronary artery stents dominate the market, with growth in femoral and popliteal artery stents also accelerating.

The U.S. market is set to expand at a 10.2% CAGR, driven by technological advancements and robust healthcare infrastructure. Europe, led by increasing heart disease cases, is expected to maintain strong growth, while Asia-Pacific shows rapid potential due to healthcare development and rising demand for medical devices.

Start-Ups and Key Developments in the Arterial Stents Market

Start-ups driving innovation in arterial stents include SLTL Group, Meril, Lepu Medical, Nano Therapeutics, and Eurocor.

• April 2021 – Eurocor launched Eurolimus, a sirolimus-eluting coronary stent with high flexibility, low strut thickness, and overexpansion capabilities.
• SLTL Group introduced ZephyrL, a cobalt chromium peripheral stent featuring a unique hybrid design for enhanced strength and visibility.

Competitive Landscape

Leading players focus on acquisitions, partnerships, and product innovation to strengthen market presence.

• April 2021 – BIOTRONIK launched tools for His-bundle conduction system implants.
• May 2022 – Medtronic received FDA approval for Onyx Frontier™ DES, enhancing deliverability and performance in complex cases.
• October 2021 – Boston Scientific released data showing the Eluvia™ Drug-Eluting Vascular Stent’s superiority over bare metal stents for peripheral artery disease.